Elyan Mazen, Khan Muhammad Asim
Case Western Reserve University, MetroHealth Medical Center, Division of Rheumatology, Cleveland, OH 44109, USA.
Curr Rheumatol Rep. 2006 Aug;8(4):255-9. doi: 10.1007/s11926-006-0005-7.
Ankylosing spondylitis (AS) is a chronic systemic rheumatic disease that primarily affects the sacroiliac joints and spine. Even with the development of tumor necrosis factor-alpha inhibitors, which have revolutionized the treatment of this disease, the combination of nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and a life-long exercise program still form the first step in its management. Multiple clinical trials have addressed the efficacy and safety of both nonselective and selective NSAIDs. Gastrointestinal toxicity remains their major side effect, with increased concern about the potential of cardiovascular toxicity, especially with the selective cyclooxygenase-2 inhibitors. A specific set of recommendations has been proposed for the management of AS.
强直性脊柱炎（AS）是一种慢性全身性风湿性疾病，主要影响骶髂关节和脊柱。即使肿瘤坏死因子-α抑制剂的出现彻底改变了这种疾病的治疗方式，但非甾体抗炎药（NSAIDs）、物理治疗和终身锻炼计划的联合应用仍是其治疗的第一步。多项临床试验探讨了非选择性和选择性NSAIDs的疗效和安全性。胃肠道毒性仍然是它们的主要副作用，人们越来越担心心血管毒性的可能性，尤其是选择性环氧化酶-2抑制剂。针对强直性脊柱炎的管理已经提出了一套具体的建议。
